Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Major safety/contraindication claims are supported, but multiple adverse-effect frequency/priority statements are unsupported, and one core product-release characterization ('continuously') is not aligned with the labeled 21-days-in/7-days-out schedule.
Category Scores
Accurate Statements
Annovera increases the risk of venous thromboembolism.
5.1 Thromboembolic Disorders and Other Vascular Conditions: "Females are at increased risk for a venous thrombotic event (VTE) when using ANNOVERA."
Annovera is warned against use in women with a history of blood clots (e.g., current or history of DVT or pulmonary embolism).
4 Contraindications: high risk arterial/venous thrombotic diseases includes current or history of DVT or pulmonary embolism; 5.1 references contraindicated high-risk thrombotic/thromboembolic diseases.
Annovera is warned against use in smokers over 35.
4 Contraindications: example includes "Smoke, if over age 35".
Annovera is warned against use in patients with certain cardiovascular conditions (e.g., cerebrovascular disease, coronary artery disease, thrombogenic valvular/rhythm diseases, uncontrolled hypertension or hypertension with vascular disease).
4 Contraindications: includes cerebrovascular disease, coronary artery disease, thrombogenic valvular/rhythm diseases, uncontrolled hypertension or hypertension with vascular disease.
Unsupported Statements
After removal of Annovera, hormone levels drop quickly.
No provided label excerpts state hormone decline kinetics after removal.
Complete clearance of Annovera can take weeks depending on individual metabolism.
No provided label excerpts discuss clearance time or metabolism-dependent clearance.
Common side effects of Annovera include vaginal irritation.
Provided label excerpts discuss vaginal irritation/ulceration risk (and erosion/ulceration reported) but do not support 'common' frequency.
Common side effects of Annovera include expulsion.
No provided label excerpts support expulsion as a common side effect.
Common side effects of Annovera include irregular bleeding.
Provided excerpts define scheduled vs unscheduled bleeding but do not support irregular bleeding being described as 'common' (frequency not shown).
Higher-volume blood loss during menstruation is reported frequently with Annovera.
No provided label excerpts support frequency for heavy menstrual blood loss.
Headaches are reported frequently with Annovera.
Provided excerpts discuss headache-related contraindications and evaluation/discontinuation but do not support 'reported frequently' frequency.
Vaginal discharge is a top concern reported with Annovera.
No provided label excerpts describe vaginal discharge as a top concern or provide frequency.
Device discomfort is a top concern reported with Annovera.
Provided excerpts mention some females/partners may notice the system, but do not support characterization as a 'top concern' or frequency.
No scheduled FDA re-review date exists for safety signals for Annovera.
No provided label excerpts address FDA re-review dates or safety signal re-evaluation timelines.
Ongoing post-marketing surveillance continues through the manufacturer’s pharmacovigilance program.
Provided 'postmarketing experience' excerpt concerns breast cancer risk studies and does not state ongoing surveillance through a manufacturer pharmacovigilance program.
Contradictions
Medium
AI Statement
Annovera is a vaginal ring that releases ethinyl estradiol and segesterone acetate continuously for up to 13 cycles.
Label Reference
3 DOSAGE FORMS AND STRENGTHS / 11 DESCRIPTION: ring releases approximate average doses over a 21-days-in / 7-days-out cycle for up to 13 cycles (not continuous release for the full cycle).
Important Omissions
The claim set does not include the labeled dosing schedule detail (21 days in/7 days out within each 28-day cycle) when describing release; this is material for accurate labeling alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported overstatements of adverse-event frequency/priority (e.g., 'common', 'frequently', 'top concern') could mislead risk perception. However, major boxed-warning-related safety (VTE risk) and key contraindication warnings (history of clots, age>35 smokers, cardiovascular conditions) are supported by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several adverse-effect frequency/priority claims and clearance kinetics are not supported by provided label excerpts; one release-description claim ('continuous release') is inconsistent with the labeled 21-days-in/7-days-out schedule.
Suggested Improvement
Replace 'continuous' release wording with the labeled 21-days-in/7-days-out regimen; remove or qualify adverse-event statements that use frequency/priority language ('common', 'frequently', 'top concern') unless supported in the provided label excerpts; omit FDA re-review date and pharmacovigilance program claims unless supported by label text.